Academic Editors: Leonid A. Gavrilov and Thomas Heinbockel
Introduction: L-carnosine has been found to have multimodal activity.
Aim: The aim of this review was to find out the efficacy of L-carnosine
in patients with age-related diseases. Methods: Clinical studies
evaluated the effect of L-carnosine on cancer, cardiovascular disease, diabetes,
and neurodegenerative disorders were searched in electronic bibliographic
databases. The protocol has been registered with PROSPERO (CRD42022314033). The
revised Cochrane risk of bias tool for randomized trials was used to assess all
of the reports for risk of bias. RevMan 5.4 was used to conduct the
meta-analysis. Results: Following the screening process, 14 papers were
selected for systematic review, with 9 of them being qualified for meta-analysis.
Many of the included studies showed that L-carnosine has potential therapeutic
activity in age related diseases. Results from the meta-analysis showed that in
diabetes mellitus, HbA1c [mean difference (MD) 95% CI = –1.25 (–2.49,
–0.022); p = 0.05; p = 0.001; I
- The dipeptide molecule L-carnosine has been found to have multimodal action.
- Efficacy of L-carnosine in patients with age-related diseases such as cancer, cardiovascular disease, diabetes, and neurodegenerative disorders is reviewed.
- Trials suggest that L-carnosine can be used to treat chemotherapy-induced toxicities, however evidence of anti-cancer action is limited.
- The current evidence does not support the use of L-carnosine in the treatment of cardiovascular disease.
- L-carnosine is beneficial to patients with diabetes mellitus and cognitive impairment.